Navigation Links
Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
Date:4/11/2013

act. With the dosing of a fifth patient in the RESONATE™-2 study, as announced today, a milestone payment of $50 million has been earned. To date, $200M in milestones have been earned and Pharmacyclics may receive up to an additional $625 million in development and regulatory milestone payments; for total potential upfront and milestone payments of $975 million.

Following regulatory approval, both Pharmacyclics and Janssen will book revenue and co-commercialize ibrutinib. In the US, Pharmacyclics will book sales and take the lead role in US commercial strategy development. Both Pharmacyclics and Janssen will share in commercialization activities. Outside the United States, Janssen will book sales and perform commercialization activities. Profits and losses from the commercialization activities will be split 50/50 on a worldwide basis. Development and commercialization activities under the collaboration will be managed through a shared governance structure. Each company will lead development for specific indications as stipulated in a global development plan. Except in certain cases, in general, development costs are shared on a 40/60 basis (Pharmacyclics 40% and Janssen 60%).

About Ibrutinib
Janssen Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib. Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulation of apoptosis, adhesion, and cell migration and homing. Through these multiple signals, BTK regulation helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a micro environment necessary for survival.

The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell mali
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
2. Pharmacyclics, Inc. Prices Public Offering of Common Stock
3. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
4. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
5. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
6. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
7. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
8. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
9. New survey finds women who suffer from migraines want a better understanding of migraine triggers
10. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
11. Cardinal Health Foundation, The Ohio State University Launch Fourth Toolkit to Help Reduce Abuse of Prescription Drugs on College Campuses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Pharma, Inc. (Nasdaq: MEIP ), an oncology company focused ... today that Daniel P. Gold , Ph.D., President and ... Healthcare Conference on Tuesday, August 11, 2015 at 3:40 p.m. ... New York . A live webcast of the ... will be available approximately one hour after the presentation. ...
(Date:8/4/2015)... Aug. 4, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Transdermal ... to their offering. ... - an approach used to deliver drugs ... an alternative to oral,intravascular, subcutaneous and transmucosal ...
(Date:8/4/2015)... 4, 2015 P&S Market ... overview, trends, DRO analysis, market segmentation, market size ... and top competitor profiles in: Global ... Development and Demand Forecast to 2020  ... Explore full reports with detailed TOC on Global ...
Breaking Medicine Technology:MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2Transdermal Drug Delivery Report 2015-2024 - Technologies, Markets, and Companies Analysis 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5
... announces that a new market research report is ... Ten World,s Leading Pharmaceutical Companies ... on performance, capabilities, goals and strategies of the ... report is designed to provide the pharmaceutical industry ...
... 16, 2010 PhotoMedex, Inc. (Nasdaq: PHMD ... today the launch of its newly designed and engineered ... integrates a strong educational component, as well as a ... patients. PhotoMedex is a global skin health ...
Cached Medicine Technology:Reportlinker Adds Top Ten World's Leading Pharmaceutical Companies 2Reportlinker Adds Top Ten World's Leading Pharmaceutical Companies 3Reportlinker Adds Top Ten World's Leading Pharmaceutical Companies 4Reportlinker Adds Top Ten World's Leading Pharmaceutical Companies 5Reportlinker Adds Top Ten World's Leading Pharmaceutical Companies 6Reportlinker Adds Top Ten World's Leading Pharmaceutical Companies 7PhotoMedex Launches New Patient-Focused XTRAC Laser Website 2
(Date:8/5/2015)... ... 2015 , ... Friendly Smiles Dental Care, is excited to announce ... and Dr. Michael J. Foley, DMD. The full service dental practice, officially welcomed both ... the Tampa Bay area, where Friendly Smiles Dental Care has provided professional dental solutions ...
(Date:8/5/2015)... ... August 05, 2015 , ... Stelari introduces their new collection, ... wear with their new line, The Earth’s Song. Combining fashion and activewear, Stelari’s new ... workout. Inspired by the Australian Outback, this collection is sure to make the spirit ...
(Date:8/5/2015)... ... August 05, 2015 , ... HealthyYOU Vending says that recent Health Code ... City & County of San Francisco are representative of initiatives across the county encouraging ... a measure from the City and County of San Francisco Board of Supervisors ...
(Date:8/5/2015)... GILBERT, AZ (PRWEB) , ... August 05, 2015 ... ... of the leading stevia brand, SweetLeaf®, was honored as one of this year’s ... recognizes women trailblazers and innovators in Arizona business. Carol May’s long-standing dedication to ...
(Date:8/4/2015)... ... August 05, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. She ... nation’s leading networking organization exclusively for professional women, boasting more than 700,000 members ...
Breaking Medicine News(10 mins):Health News:Friendly Smiles Dental Care Welcomes New Doctors 2Health News:Stelari: Bohemian Chic Activewear Line 2Health News:Stelari: Bohemian Chic Activewear Line 3Health News:HealthyYOU Vending says San Francisco’s ‘Soda Free Summer’ Initiative and Other Recent Health-related Ordinances Demonstrate Why Healthy Vending is a Growing Industry 2Health News:HealthyYOU Vending says San Francisco’s ‘Soda Free Summer’ Initiative and Other Recent Health-related Ordinances Demonstrate Why Healthy Vending is a Growing Industry 3Health News:Carol May Named One of the Most Influential Woman in Arizona 2Health News:Carol May Named One of the Most Influential Woman in Arizona 3Health News:Carol May Named One of the Most Influential Woman in Arizona 4Health News:NAPW Inducts Deborah Stevens, Executive Assistant to Chairman and CEO at Mirion Technologies, Inc., Into its VIP Woman of the Year Circle 2
... and development support to existing health care dramatically improves ... ,Researchers from the John Hopkins Bloomberg School ... sites which was designed to bridge the gap between ... practice to provide enhanced services such as home visits, ...
... suggests children undergoing liver transplants may fare better if ... transplants began, steroids have played a major role in ... However, the treatment is not without side effects, especially ... blood pressure, elevated blood cholesterol, and impaired growth in ...
... New research reports, patients who were treated for depression ... vitamin B12 in their blood.// ,An increasing amount ... B and depression, but the specifics have not been ... relationship of vitamin B12 and the treatment of depression. ...
... the Dana-Farber Cancer Institute shows more than half of ... treatment-related infertility problems.// ,Nearly 700 members of ... 40 years old or younger were surveyed. More than ... were concerned about being infertile as a result of ...
... often leading to diabetes and cardiovascular disease. Being overweight ... resistant, but not all overweight or obese people are ... resistance, however, it is too difficult to administer to ... come up with a simple way to identify overweight ...
... cesarean section during their first pregnancy are at an increased ... ,Researchers are uncertain why the link between C-section delivery ... cause. ,Researchers in Scotland studied data for all ... and 1998. They then compared the data to records from ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: